Mumbai, February 23, 2026 (Monday) — Edelweiss Financial Services Limited and Cohance Lifesciences Limited witnessed significant block deal transactions during the morning block deal window on Monday, with a combined traded value of ₹353.62 crore.
The transactions were executed in Session 1 of the block deal window, which operates between 8:45 AM and 9:00 AM on stock exchanges.
Block Deal Details
| Company | Series | Deal Price (₹) | Shares Traded | Transaction Value (₹ Crore) | Closing Price (₹) | % Change |
|---|---|---|---|---|---|---|
| Edelweiss Financial Services | BL | 118.00 | 1,00,00,000 | 118.00 | 121.10 | -2.56 |
| Cohance Lifesciences | BL | 306.00 | 77,00,000 | 235.62 | 305.40 | 0.20 |
Transaction Snapshot
- Edelweiss Financial Services Limited
- 1 crore shares changed hands at ₹118 per share
- Total deal value stood at ₹118 crore
- Cohance Lifesciences Limited
- 77 lakh shares traded at ₹306 per share
- Aggregate deal value stood at ₹235.62 crore
Price Movement
Edelweiss closed at ₹121.10, while Cohance Lifesciences ended at ₹305.40. The percentage change reflects movement based on exchange-adjusted reference pricing methodology.Block deals are large, privately negotiated transactions executed through a separate trading window and typically indicate stake transfers between institutional participants.
About the Companies
Edelweiss Financial Services Limited is a diversified financial services group engaged in credit, asset management, and insurance businesses.Cohance Lifesciences Limited operates in the pharmaceutical and life sciences segment, focusing on active pharmaceutical ingredients and contract development manufacturing services.
Both companies are listed on the NSE and BSE.
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.